Estrogen receptor modulators: Identification and structure-activity relationships of potent ERα-selective tetrahydroisoquinoline ligands

Journal of Medicinal Chemistry

Volumn 46, Issue 14, 2003, Pages 2945-2957

  Renaud, Johanne ^a   Bischoff, Serge François ^a   Buhl, Thomas ^a   Floersheim, Philipp ^a   Fournier, Brigitte ^a   Halleux, Christine ^a   Kallen, Joerg ^a   Keller, Hansjoerg ^a   Schlaeppi, Jean Marc ^a   Stark, Wilhelm ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; ESTRADIOL; ESTRONE; LASOFOXIFENE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BONE REMODELING; CELL STRAIN MCF 7; CRYSTAL STRUCTURE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LIGAND BINDING; RECEPTOR AFFINITY; REPORTER GENE; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; BINDING SITES; BIOLOGICAL AVAILABILITY; CELL DIVISION; CRYSTALLOGRAPHY, X-RAY; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HELA CELLS; HUMANS; ISOQUINOLINES; LIGANDS; MODELS, MOLECULAR; RADIOLIGAND ASSAY; RALOXIFENE; RATS; RECEPTORS, ESTROGEN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0038798608     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030086h     Document Type: Article

References (47)

1. Eriksen, E. F.; Axelrod, D. W.; Melsen, F. Bone Histomorphometry. Raven Press: New York, 1994; pp 3-12.
2. Rickard, D. J.; Subramaniam, M.; Spelsberg, T. C. Molecular and Cellular Mechanisms of Estrogen Action on the Skeleton. J. Cell. Biochem. 1999, S32/33, 123-132.
3. (a) Dechering, K.; Boersma, C.; Mosselman, S. Estrogen Receptors α and β: Two Receptors of a Kind? Curr. Med. Chem. 2000, 7, 561-576;
4. (b) Mosselman, S.; Polman, J.; Dijkema, R. ERβ: Identification and Characterization of a Novel Human Estrogen Receptor. FEBS Lett. 1996, 392, 49-53.
5. (a) Taylor, A. H.; Al-Azzawi, F. Immunolocalisation of Oestrogen Receptor Beta in Human Tissues. J. Mol. Endocrinol. 2000, 24, 145-155 and references therein.
6. Pike, A. C. W.; Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A.-G.; Engström, O.; Ljunggren, J.; Gustafsson, J.-A.̊; Carlquist, M. Structure of the Ligand-Binding Domain of Oestrogen Receptor Beta in the Presence of a Partial Agonist and a Full Antagonist. EMBO J. 1999, 18, 4608-4618.
7. (a) Bilezikian, J. P. Sex Steroids, Mice and Men: When Androgens and Estrogens Get Very Close to Each Other. J. Bone Miner. Res. 2002, 17, 563-566;
8. (b) Sims, N. A.; Dupont, S.; Krust, A.; Clement-Lacroix, P.; Minet, D.; Resche-Rigon, M.; Gaillard-Kelly, M.; Baron, R. Deletion of Estrogen Receptors Reveals a Regulatory Role for Estrogen Receptors-β in Bone Remodeling in Females but Not in Males. Bone 2002, 30, 18-25.
9. (a) Sato, M.; Grese, T. A.; Dodge, J. A.; Bryant, H. U.; Turner, C. H. Emerging Therapies for the Prevention or Treatment of Postmenopausal Osteoporosis. J. Med. Chem. 1999, 42, 1-24.
10. (b) Kanis, J. A. Estrogens, the Menopause, and Osteoporosis. Bone 1996, 19, 185S-190S.
11. (a) Torgerson, D. J. HRT and its Impact on the Menopause, Osteoporosis and Breast Cancer. Exp. Opin. Pharmacother. 2000, 1, 1163-1169.
12. (b) Palacios, S. Current Perspectives on the Benefits of HRT in Menopausal Women. Maturitas 1999, 33, S1-S13.
13. Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. JAMA 2002, 288, 321-333.
14. For recent reviews about SERMs, see: (a) Miller, C. P. SERMs: Evolutionary Chemistry, Revolutionary Biology. Curr. Pharm. Des. 2002, 8, 2089-2111. (b) Labrie, F.; Labrie, C.; Bélanger, A.; Giguere, V.; Simard, J.; Mérand, Y.; Gauthier, S.; Luu-The, V.; Candas, B.; Martel, C.; Luo, S. Pure Selective Estrogen Receptor Modulators, New Molecules Having Absolute Cell Specificity Ranging from Pure Antiestrogenic to Complete Estrogen-Like Activities. Adv. Protein Chem. 2001, 56, 293-369. (c) Dutertre, M.; Smith, C. L. Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action. J. Pharmacol. Exp. Ther. 2000, 295, 431-437 and references therein; (d) McDonnell, D. P. The Molecular Pharmacology of SERMs. TEM 1999, 10, 301-311 and references therein.
15. For recent reviews about SERMs, see: (a) Miller, C. P. SERMs: Evolutionary Chemistry, Revolutionary Biology. Curr. Pharm. Des. 2002, 8, 2089-2111. (b) Labrie, F.; Labrie, C.; Bélanger, A.; Giguere, V.; Simard, J.; Mérand, Y.; Gauthier, S.; Luu-The, V.; Candas, B.; Martel, C.; Luo, S. Pure Selective Estrogen Receptor Modulators, New Molecules Having Absolute Cell Specificity Ranging from Pure Antiestrogenic to Complete Estrogen-Like Activities. Adv. Protein Chem. 2001, 56, 293-369. (c) Dutertre, M.; Smith, C. L. Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action. J. Pharmacol. Exp. Ther. 2000, 295, 431-437 and references therein; (d) McDonnell, D. P. The Molecular Pharmacology of SERMs. TEM 1999, 10, 301-311 and references therein.
16. For recent reviews about SERMs, see: (a) Miller, C. P. SERMs: Evolutionary Chemistry, Revolutionary Biology. Curr. Pharm. Des. 2002, 8, 2089-2111. (b) Labrie, F.; Labrie, C.; Bélanger, A.; Giguere, V.; Simard, J.; Mérand, Y.; Gauthier, S.; Luu-The, V.; Candas, B.; Martel, C.; Luo, S. Pure Selective Estrogen Receptor Modulators, New Molecules Having Absolute Cell Specificity Ranging from Pure Antiestrogenic to Complete Estrogen-Like Activities. Adv. Protein Chem. 2001, 56, 293-369. (c) Dutertre, M.; Smith, C. L. Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action. J. Pharmacol. Exp. Ther. 2000, 295, 431-437 and references therein; (d) McDonnell, D. P. The Molecular Pharmacology of SERMs. TEM 1999, 10, 301-311 and references therein.
17. For recent reviews about SERMs, see: (a) Miller, C. P. SERMs: Evolutionary Chemistry, Revolutionary Biology. Curr. Pharm. Des. 2002, 8, 2089-2111. (b) Labrie, F.; Labrie, C.; Bélanger, A.; Giguere, V.; Simard, J.; Mérand, Y.; Gauthier, S.; Luu-The, V.; Candas, B.; Martel, C.; Luo, S. Pure Selective Estrogen Receptor Modulators, New Molecules Having Absolute Cell Specificity Ranging from Pure Antiestrogenic to Complete Estrogen-Like Activities. Adv. Protein Chem. 2001, 56, 293-369. (c) Dutertre, M.; Smith, C. L. Molecular Mechanisms of Selective Estrogen Receptor Modulator (SERM) Action. J. Pharmacol. Exp. Ther. 2000, 295, 431-437 and references therein; (d) McDonnell, D. P. The Molecular Pharmacology of SERMs. TEM 1999, 10, 301-311 and references therein.
18. Maricic, M.; Gluck, O. Review of Raloxifene and its Clinical Applications in Osteoporosis. Expert Opin. Pharmacother. 2002, 3, 767-775
19. White, I. N. H. The Tamoxifen Dilemma. Carcinogenesis 1999, 20, 1153-1160.
20. Grese, T. A.; Sluka, J. P.; Bryant, H. U.; Cullinan, G. J.; Glasebrook, A. L.; Jones, C. D.; Matsumoto, K.; Palkowitz, A. D.; Sato, M.; Termine, J. D.; Winter, M. A.; Yang, N. N.; Dodge, J. A. Molecular Determinants of Tissue Selectivity in Estrogen Receptor Modulators. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 14105-14110.
21. Rosati, R. L.; Jardine, P. Da Silva; Cameron, K. O.; Thompson, D. D.; Ke, H. Z.; Toler, S. M.; Brown, T. A.; Pan, L. C.; Ebbinghaus, C. F.; Reinhold, A. N.; Elliott, N. C.; Newhouse, B. N.; Tjoa, C. M.; Sweetnam, P. M.; Cole, M. J.; Arriola, M. W.; Gauthier, J. W.; Crawford, D. T.; Nickerson, D. F.; Pirie, C. M.; Qi, H.; Simmons, H. A.; Tkalcevic, G. T. Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene. J. Med. Chem. 1998, 41, 2928-2931. In addition, raloxifene possesses two phenolic OHs, both of which undergo glucuronidation, see: Dodge, J. A.; Lugar, C. W.; Cho, S.; Short, L. L.; Sato, M.; Yang, N. N.; Spangle, L. A.; Martin, M. J.; Phillips, D. L.; Glasebrook, A. L.; Osborne, J. J.; Frolik, C. A.; Bryant, H. U. Evaluation of the Major Metabolites of Raloxifene as Modulators of Tissue Selectivity. J. Steroid Biochem. Mol. Biol. 1997, 61, 97-106.
22. Rosati, R. L.; Jardine, P. Da Silva; Cameron, K. O.; Thompson, D. D.; Ke, H. Z.; Toler, S. M.; Brown, T. A.; Pan, L. C.; Ebbinghaus, C. F.; Reinhold, A. N.; Elliott, N. C.; Newhouse, B. N.; Tjoa, C. M.; Sweetnam, P. M.; Cole, M. J.; Arriola, M. W.; Gauthier, J. W.; Crawford, D. T.; Nickerson, D. F.; Pirie, C. M.; Qi, H.; Simmons, H. A.; Tkalcevic, G. T. Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene. J. Med. Chem. 1998, 41, 2928-2931. In addition, raloxifene possesses two phenolic OHs, both of which undergo glucuronidation, see: Dodge, J. A.; Lugar, C. W.; Cho, S.; Short, L. L.; Sato, M.; Yang, N. N.; Spangle, L. A.; Martin, M. J.; Phillips, D. L.; Glasebrook, A. L.; Osborne, J. J.; Frolik, C. A.; Bryant, H. U. Evaluation of the Major Metabolites of Raloxifene as Modulators of Tissue Selectivity. J. Steroid Biochem. Mol. Biol. 1997, 61, 97-106.
23. A similar route using intermediates with different protecting groups has been reported: Nagarajan, K.; Talwalker, P. K.; Kulkarni, C. L.; Shah, R. K.; Shenoy, S. J.; Prabhu, S. S. Antiimplantation Agents: Part II 1,2-Diaryl-1,2,3,4-tetrahydroisoquinolines. Indian J. Chem. 1985, 24B, 83-97.
24. Ohkubo, M.; Kuno, A.; Katsuta, K.; Ueda, Y.; Shirakawa, K.; Nakanishi, H.; Nakanishi, I.; Kinoshita, T.; Takasugi, H. Studies on Cerebral Protective Agents. IX. Synthesis of Novel 1,2,3,4-Tetrahydroisoquinolines as N-Methyl-D-Aspartate Antagonists. Chem. Pharm. Bull. 1996, 44, 95-102.
25. (a) Shanker, P. S.; Subba Rao, G. S. R. Synthesis of Isoquinolines from Indanones: Total Synthesis of Illudinine. Indian J. Chem., Sect. B, 1993, 32B, 1209-1213.
26. (b) earlier reports had demonstrated that the methoxy group para to the carbonyl functionality of the indanone favors the migration of the alkyl over the aryl substituent in the presence of sulfuric acid, see: Tomita, M.; Minami, S.; Uyeo, S. The Schmidt Reaction with Benzocycloalkenones. J. Chem. Soc. C 1969, 183-188.
27. Sugahara, M.; Ukita, T. A Facile Copper-Catalyzed Ullmann Condensation: N-Arylation of Heterocyclic Compounds Containing an -NHCO- Moiety. Chem. Pharm. Bull. 1997, 45, 719-721.
28. 3-N,N-Dimethylaniline: A New Benzyl and Allyl Ether Cleavage Reagent. Tetrahedron Lett. 1991, 32, 1321-1324.
29. (a) The methoxy analogues of 17a and 18a were disclosed in an earlier publication, the pyrrolidinoethoxy derivative showing antiimplantation activity while the piperidinoethoxy analogue did not.
30. See ref 15. (b) Tetrahydroisoquinoline 17a was previously reported in the patent literature as an estrogenic agent. The biological data for this compound were not disclosed however. See: Cameron, K. O.; Jardine, P. A. DaSilva. Preparation of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists. PCT Int. Appl. WO 9621656, 1996.
31. Dukes, M.; Chester, R.; Yarwood, L.; Wakeling, A. E. Effects of a Non-Steroidal Pure Antioestrogen, ZM 189, 154, on Oestrogen Target Organs of the Rats Including Bones. J. Endocrinol. 1994, 141, 335-341.
32. (a) Grese, T. A.; Adrian M. D.; Phillips, D. L.; Shetler, P. K.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. Photochemical Synthesis of N-Arylbenzophenanthridine Selective Estrogen Receptor Modulators (SERMs). J. Med. Chem. 2001, 44, 2857-2860.
33. (b) Grese, T. A.; Cho, S.; Finley, D. R.; Godfrey, A. G.; Jones, C. D.; Lugar, C. W., III; Martin, M. J.; Matsumoto, K.; Pennington, L. D.; Winter, M. A.; Adrian, M. D.; Cole, H. W.; Magee, D. E.; Phillips, D. L.; Rowley, E. R.; Short, L. L.; Glasebrook, A. L.; Bryant, H. U. Structure-Activity Relationships of Selective Estrogen Receptor Modulators: Modifications to the 2-Arylbenzothiophene Core of Raloxifene. J. Med. Chem. 1997, 40, 146-167.
34. Shang, Y.; Brown, M. Molecular Determinants for the Tissue Specificity of SERMs. Science 2000, 295, 2465-2468.
35. (a) Labrie, F.; Labrie, C.; Bélanger, A.; Simard, J.; Gauthier, S.; Luu-The, V.; Mérand, Y.; Giguere, V.; Candas, B.; Luo, S.; Martel, C.; Singh, S. M.; Fournier, M.; Coquet, A.; Richard, V.; Charbonneau, R.; Charpenet, G.; Tremblay, A.; Tremblay, G.; Cusan, L.; Veilleux, R. EM-652 (SCH 57068), a Third Generation SERM Acting As Pure Antiestrogen in the Mammary Gland and Endometrium. J. Steroid Biochem. Mol. Biol. 1999, 69, 51-84 and references therein.
36. (b) Poulin, R.; Mérand, Y.; Poirier, D.; Lévesque, C.; Dufour, J. M.; Labrie, F. Antiestrogenic Properties of Keoxifene, Trans-4-Hydroxytamoxifen, and ICI 164384, a New Steroidal Antiestrogen, in ZR-75-1 Human Breast Cancer Cells. Breast Cancer Res. Treat. 1989, 14, 65-76.
37. (c) DeFriend, D. J.; Anderson, E.; Bell, J.; Wilks, D. P.; West, C. M.; Mansel, R. E.; Howell, A. Effects of 4-Hydroxytamoxifen and a Novel Pure Antioestrogen (ICI 182780) on the Clonogenic Growth of Human Breast Cancer Cells in Vitro. Br. J. Cancer 1994, 70, 204-211.
38. (d) Reddel, R. R.; Sutherland, R. L. Tamoxifen Stimulation of Human Breast Cancer Cell Proliferation in Vitro: a Possible Model for Tamoxifen Tumour Flare. Eur. J. Cancer Clin. Oncol. 1984, 20, 1419-1424.
39. Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engström, O.; Öhman, L.; Greene, G. L.; Gustafsson, J.-A; Carlquist, M. Molecular Basis of Agonism and Antagonism in the Oestrogen Receptor. Nature 1997, 389, 753-758.
40. Shiau, A. K.; Barstad, D.; Loria, P. M.; Cheng, L.; Kushner, P. J.; Agard, D. A.; Greene, G. L. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of this Interaction by Tamoxifen. Cell 1998, 95, 927-937.
41. The crystal structure of a triple cysteine to serine mutant ERα-LBD complexed with estradiol was reported prior to our work. See: Gangloff, M.; Ruff, M.; Eiler, S.; Duclaud, S.; Wurtz, J.M.; Moras, D. Crystal Structure of a Mutant hERα Ligand-Binding Domain Reveals Key Structural Features for the Mechanism of Partial Agonism. J. Biol. Chem. 2001, 276, 15059-15065.
42. (a) Bury, P. S.; Christiansen, L. B.; Jacobsen, P.; Jørgensen, A. S.; Kanstrup, A.; Naerum, L.; Bain, S.; Fledelius, C.; Gissel, B.; Hansen, B. S.; Korsgaard, N.; Thorpe, S. M.; Wassermann, K. Synthesis and Pharmacological Evaluation of Novel cis-3,4-Diaryl-hydroxychromanes as High Affinity Partial Agonists for the Estrogen Receptor. Bioorg. Med. Chem. 2002, 10, 125-145.
43. (b) Gauthier, S.; Caron, B.; Cloutier, J.; Dory, Y. L.; Favre, A.; Larouche, D.; Mailhot, J.; Ouellet, C.; Schwerdtfeger, A.; Leblanc, G.; Martel, C.; Simard, J.; Mérand, Y.; Bélanger, A.; Labrie, C.; Labrie, F. (S)-(+)-4-[7-(2,2-Dimethyl-1-oxopropoxy)4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl]-2,2-Dimethylpropanoate (EM-800): A Highly Potent, Specific, and Orally Active Nonsteroidal Antiestrogen. J. Med. Chem. 1997, 40, 2117-2122.
44. Berthois, Y.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Phenol Red in Tissue Culture Media is a Weak Estrogen: Implications Concerning the Study of Estrogen-Responsive Cells in Culture. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 2496-2500.
45. This assay solution contains PES (phenazine ethosulfate), an electron coupling reagent and MTS (3-(4,5-dimethythiazol-2-yl)5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl) -2H-tetrazolium or Owen's reagent). MTS is bioreduced by the cells into a coloured formazan product soluble in the culture medium.
46. (a) Balaguer, P.; Boussioux, A.-M.; Demirpence, E.; Nicolas, J.C. Reporter Cell Lines are Useful Tools for Monitoring Biological Activity of Nuclear Receptor Ligands. Luminescence 2001, 16, 153-158;
47. (b) Balaguer, P.; Francois, F.; Comunale, F.; Fenet, H.; Boussioux, A.-M.; Pons, M.; Nicolas, J.-C. and Casellas, C. Reporter Cell Lines to Study the Estrogenic Effects of Xenoestrogens. Sci. Total Environ. 1999, 233, 47-56.